The Gillett Health Podcast New Hair Loss Medication
Dec 12, 2025
Exciting developments in hair loss treatment are on the horizon with a new medication, PP405, showing promising results. The hosts dive into how it targets scalp stem cells to potentially restore hair follicles. They discuss the implications of a 31% density increase and the importance of context in interpreting study data. Concerns about non-responders and the study's timeframe are raised, along with the caution against using unregulated compounds. Plus, they explore other topical options in the hair-loss arena!
AI Snips
Chapters
Transcript
Episode notes
Early Data Are Just A Teaser
- PP405 is a promising hair-loss candidate but current data are limited to a phase 2A teaser release.
- Kyle Gillett, MD and James O'Hara emphasize that the published results are preliminary and likely investor-focused.
PP405 Targets Stem Cells, Not DHT
- Current hair-loss treatments fall into two main groups: anti-androgens and growth agonists.
- PP405 differs because it targets scalp stem cells rather than androgen pathways.
Stabilizing Stem Cells Could Reverse Miniaturization
- The drug's theorized benefit is stabilizing follicle stem cells to reverse miniaturization.
- Kyle Gillett, MD warns durability and root-cause prevention remain uncertain without long-term data.